This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Psst... These Drug Firms Are Getting Bought: BioBuzz

BOSTON, Mass. ( TheStreet) -- Look for U.S. pharmaceutical companies to ratchet up acquisition activity -- the target being biotech and specialty drug firms, according to Credit Suisse pharmaceuticals analyst Catherine Arnold, in a research note published Thursday morning.

Arnold believes that the cost-saving mega-mergers between Big Pharma are largely done, so now Big Pharma will focus on boosting revenue growth through smaller acquisitions.

So, who's going to buy whom, according to Arnold?

Appetizing takeover targets include Alexion Pharmaceuticals (ALXN - Get Report), Amylin Pharmaceuticals (AMLN), Vertex Pharmaceuticals (VRTX - Get Report), BioMarin (BMRN - Get Report), Rigel (RIGL - Get Report) and Salix Pharmaceuticals (SLXP).

The potential buyers include Abbott Labs (ABT), Bristol-Myers Squibb (BMY), Eli Lilly (LLY), Johnson & Johnson (JNJ), Gilead Sciences (GILD) and Forest Labs (FRX).

Where is Rigel Partner in Wake of Stock Sale?

Rigel Pharmaceuticals is selling more stock, but wasn't the small drug maker supposed to raise money by partnering its experimental rheumatoid arthritis drug?

Announced Wednesday after the close, Rigel said it intends to sell 6 million shares with an over-allotment option for another 900,000-shares. At Wednesday's closing price, the offering would gross just under $53 million.

Rigel ended the second quarter with about $80 million in cash, enough to get the company into the middle of next year.

The new offering will bolster the company's bank account and could help it at the negotiating table as it seeks a partner for R788, a novel pill for rheumatoid arthritis.

Or, does this new offering signal that Rigel is having trouble finding a partner interested in R788?

The drug is certainly not without controversy. An oral pill for rheumatoid arthritis could be a very big deal given that current medicines -- most notably the so-called "anti-TNFs" like Amgen's (AMGN) Enbrel and Abbott Labs' Humira -- are given by injection.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ALXN $181.34 -1.60%
AUXL $36.47 -0.16%
BMRN $120.91 -0.61%
SLXP $172.81 0.09%
RIGL $4.09 -1.92%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs